Search Results - technology+classifications+%3e+diagnostics+%3e+biomarkers

175 Results

Sort By:

RASAL1 and PTEN Co-Alterations Predict Cancer Aggressiveness

Value Proposition· Improved Prognostic Accuracy: Dual detection of RASAL1 and PTEN alterations enables highly accurate identification of aggressive cancers and risk stratification. These biomarkers provide greater precision in identifying aggressive cancers compared to established markers, enabling better patient management. · Pan-Cancer...

Published: 1/22/2026 | Inventor(s): Michael Xing, Xiaopei Shen, Jie Tan

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Companion Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Precision Medicine Tools, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > Prognostics Biomarkers, Clinical and Disease Specializations > Oncology

Partitioning of Human Mesenchymal Stem Cells based on Expression of CD201 or CD141

Partitioning of Human Mesenchymal Stem Cells based on Expression of CD201 or CD141C17534 Unmet NeedBone defects are common and devastating conditions that are addressed in over 2.2 million surgeries yearly. Additionally, the biomedical burden of soft tissue defects is likewise enormous, estimated to be addressed in 5.2 million surgeries yearly. Autologous...

Published: 1/22/2026 | Inventor(s): Aaron James

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Stem Cells

Monoclonal Antibody for Cancer Metastasis

Unmet Need· It is projected that there will be about 1.9 million cancer cases, and 6 thousand cancer deaths within the US in the year 2023 (Siegel, 2021). mAb immunotherapy has been found to be less damaging and less invasive to rapidly dividing normal tissues when compared to current tumor therapy treatments such as surgery, radiation, and chemotherapy....

Published: 1/22/2026 | Inventor(s): Andrew Ewald, Matthew Dunworth, Shannon Radomski, Livia Casciola-Rosen, Antony Rosen

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

In vivo and in vitro Role of Lactosylceramide Synthase (LCS) in Angiogenesis and LCS (B1, 4GalT-V) as a Bio-marker for Human Colon Cancer

Description: C10539: Use of Biomarker for Colon Cancer Diagnosis Value Proposition: ADVANTAGES • Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis. • Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers...

Published: 1/22/2026 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Colorectal Cancer, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer

Anti- TFAM Antibody Detection Assay Predicting Lethal Cardiovascular Events, damage accrual and malignancy in Lupus Patients

Value Proposition:· Specific biomarker for the detection of major adverse events, including thrombosis, in systemic lupus patients.· Serum samples are easily accessible for biomarker detection.· High specificity for thrombotic (clotting) event risk, malignancy and death.· Leverages common laboratory tests for detection for smooth...

Published: 1/22/2026 | Inventor(s): Felipe Andrade, Jose de Jesus Eduardo Gomez-Bañuelos

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity > Systemic Lupus Erythematosus, Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Research Tools > Assays, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics

Methylated Markers for the Detection of Cervical Cancer

Unmet need:According to WHO, cervical cancer represents the fourth most common female cancer world-wide, with approximately 600,000 new cases as well as 300,000 deaths in 2020 alone (see WHO). Cervical cancer screening efforts aim to detect cancerous lesions in the cervix to enable earlier treatment. The main screening modalities include a Pap test...

Published: 1/22/2026 | Inventor(s): Saraswati Sukumar, MaryJo Fackler, Deyin Xing

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Cervical Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications, Technology Classifications > Diagnostics

Autoantibody-based biomarker for systemic lupus erythematosus (SLE)

Unmet NeedPatients with systemic lupus erythematosus (SLE) have a range of symptoms across multiple organ systems. The primary diagnostic test for SLE is the antinuclear antibodies (ANA) test. However, there is disagreement between laboratories as to which ANA staining patterns are considered diagnostic. Additionally, as autoantibodies are present in...

Published: 1/22/2026 | Inventor(s): Felipe Andrade, Jose de Jesus Eduardo Gomez-Bañuelos

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity > Systemic Lupus Erythematosus, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers

Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD

Value PropositionTreatment readily acts via subcutaneous injection and crosses the blood-brain barrier without extra formulation or drug delivery mechanism.Treatment significantly reduces pathological and behavioral phenotypes from toxic proteins coded by genetic defects in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which...

Published: 1/22/2026 | Inventor(s): Shuying Sun, Zhe Zhang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Clinical and Disease Specializations > Neurology > Dementia, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > Biomarkers

Activating Mutations in GNAQ Sensitive to Antibiotic; Novel Molecular Pathway and Treatment Target for Capillary Malformations and Related Syndromes

Value Proposition: · Antibiotic treatment strategy for capillary malformations and Sturge-Weber Syndrome. · Selectively targets endothelial cells with the pathogenic GNAQ mutations using puromycin · Inhibits cell proliferation and reduces cell survival via activation of TRP6/NFAT signaling pathway · Compatible with various drug...

Published: 1/22/2026 | Inventor(s): Anne Comi, Jonathan Pevsner, Zhenhua Huang, Douglas Marchuk

Keywords(s): Biomarker, Disease Indication, Genetic Disorders, Mechanism-of-action Biomarker, Skin Disorders, Sturge-Weber Syndrome, Sturge-Weber Syndrome (SWS), Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Dermatology, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Dermatology > Sturge-Weber Syndrome

A DNA methylation and genotype specific biomarker of suicide attempt

Novel Biomarkers for Predicting Suicide RiskJHU REF: [C12394]Invention Novelty: This invention provides DNA methylation-based biomarkers for predicting suicide risk. Value Proposition: Almost 30,000 people die of suicide each year in the United States, and 1 million people die worldwide. In the teenage population, it is the second leading cause of...

Published: 1/22/2026 | Inventor(s): Holly Wilcox, Zachary Kaminsky

Keywords(s): Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, Epigenetic, In Vitro Diagnostics, In Vitro Diagnostics (Old), Methylation, Prognostic Biomarker, Psychiatric Diseases, Suicidal Impulses, Suicide/Suicidal Impulses

Category(s): Clinical and Disease Specializations, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Clinical and Disease Specializations > Psychiatry > Suicidal Impulses

1 2 3 4 5 6 7 8 9 10 ...